ZA201500856B - Ethynyl derivatives as modulators of mglur5 receptor activity - Google Patents

Ethynyl derivatives as modulators of mglur5 receptor activity

Info

Publication number
ZA201500856B
ZA201500856B ZA2015/00856A ZA201500856A ZA201500856B ZA 201500856 B ZA201500856 B ZA 201500856B ZA 2015/00856 A ZA2015/00856 A ZA 2015/00856A ZA 201500856 A ZA201500856 A ZA 201500856A ZA 201500856 B ZA201500856 B ZA 201500856B
Authority
ZA
South Africa
Prior art keywords
modulators
receptor activity
mglur5 receptor
ethynyl derivatives
ethynyl
Prior art date
Application number
ZA2015/00856A
Other languages
English (en)
Inventor
Eric Vieira
Daniel Rueher
Lothar Lindemann
Heinz Stadler
Antonio Ricci
Georg Jaeschke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA201500856B publication Critical patent/ZA201500856B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2015/00856A 2012-10-18 2015-02-05 Ethynyl derivatives as modulators of mglur5 receptor activity ZA201500856B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12188940 2012-10-18
PCT/EP2013/071500 WO2014060398A1 (en) 2012-10-18 2013-10-15 Ethynyl derivatives as modulators of mglur5 receptor activity

Publications (1)

Publication Number Publication Date
ZA201500856B true ZA201500856B (en) 2016-08-31

Family

ID=47049067

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/00856A ZA201500856B (en) 2012-10-18 2015-02-05 Ethynyl derivatives as modulators of mglur5 receptor activity

Country Status (26)

Country Link
US (1) US9227959B2 (enExample)
EP (1) EP2909180B1 (enExample)
JP (1) JP5989250B2 (enExample)
KR (1) KR101684816B1 (enExample)
CN (1) CN104718192B (enExample)
AR (1) AR093042A1 (enExample)
AU (1) AU2013333988B2 (enExample)
BR (1) BR112015006454A8 (enExample)
CA (1) CA2882520A1 (enExample)
CL (1) CL2015000891A1 (enExample)
CO (1) CO7200248A2 (enExample)
CR (1) CR20150144A (enExample)
EA (1) EA025667B1 (enExample)
ES (1) ES2599553T3 (enExample)
IL (1) IL237380A (enExample)
MA (1) MA38012B1 (enExample)
MX (1) MX2015004898A (enExample)
MY (1) MY168937A (enExample)
NZ (1) NZ705144A (enExample)
PE (1) PE20150629A1 (enExample)
PH (1) PH12015500398A1 (enExample)
SG (1) SG11201501392TA (enExample)
TW (1) TWI490208B (enExample)
UA (1) UA114529C2 (enExample)
WO (1) WO2014060398A1 (enExample)
ZA (1) ZA201500856B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA114008C2 (xx) * 2012-10-18 2017-04-10 Похідні етинілу як модулятори активності рецептора mglur5
AU2016273751B2 (en) * 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
EP3353161B1 (en) * 2015-09-25 2021-07-21 The United States of America, as represented by the Secretary, Department of Health and Human Services Triazole derivatives as p2y14 receptor antagonists
RS62517B1 (sr) 2017-12-08 2021-11-30 Boehringer Ingelheim Int Derivati imidazopiridina i njihova upotreba kao leka
EA202191014A1 (ru) * 2018-10-17 2021-11-09 Бёрингер Ингельхайм Интернациональ Гмбх Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства
TW202035396A (zh) 2018-10-17 2020-10-01 德商百靈佳殷格翰國際股份有限公司 4-吡啶基甲基-嗎啉衍生物及其作為藥物之用途
CN112888684B (zh) * 2018-10-17 2023-10-10 勃林格殷格翰国际有限公司 4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
WO2020245136A1 (en) 2019-06-04 2020-12-10 Boehringer Ingelheim International Gmbh Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
KR20100033981A (ko) * 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
WO2013049255A1 (en) * 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors

Also Published As

Publication number Publication date
MA38012B1 (fr) 2016-12-30
BR112015006454A8 (pt) 2019-08-20
HK1207639A1 (zh) 2016-02-05
EP2909180B1 (en) 2016-10-05
MX2015004898A (es) 2015-07-21
CR20150144A (es) 2015-04-30
KR20150055044A (ko) 2015-05-20
WO2014060398A1 (en) 2014-04-24
AU2013333988A1 (en) 2015-02-26
BR112015006454A2 (pt) 2017-07-04
AR093042A1 (es) 2015-05-13
PE20150629A1 (es) 2015-05-11
US20150225385A1 (en) 2015-08-13
ES2599553T3 (es) 2017-02-02
US9227959B2 (en) 2016-01-05
SG11201501392TA (en) 2015-05-28
IL237380A0 (en) 2015-04-30
JP2015531392A (ja) 2015-11-02
KR101684816B1 (ko) 2016-12-20
CO7200248A2 (es) 2015-02-27
EP2909180A1 (en) 2015-08-26
JP5989250B2 (ja) 2016-09-07
TW201420571A (zh) 2014-06-01
NZ705144A (en) 2018-09-28
TWI490208B (zh) 2015-07-01
AU2013333988B2 (en) 2017-03-09
PH12015500398B1 (en) 2015-04-27
CL2015000891A1 (es) 2015-09-11
UA114529C2 (uk) 2017-06-26
PH12015500398A1 (en) 2015-04-27
MA38012A1 (fr) 2016-05-31
EA201590699A1 (ru) 2015-07-30
MY168937A (en) 2019-01-10
CA2882520A1 (en) 2014-04-24
IL237380A (en) 2017-02-28
CN104718192A (zh) 2015-06-17
CN104718192B (zh) 2016-08-31
EA025667B1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
SG2014009260A (en) Aminopyrimidine derivatives for use as modulators of kinase activity
IL237380A (en) Ethylene derivatives as modulators of mglur5 receptor activity
IL231783A0 (en) History of ethinyl as allosteric modulators of 5mglur
IL228835A (en) Ethylene history as positive allosteric modulators of 5mglur
PL3055315T3 (pl) Tiazolopirymidynony jako modulatory aktywności receptora nmda
IL236448A (en) Indulcarbonitriles as selective modulators of the androgen receptor
IL237217A (en) Ethinyl derivatives as modulators of mglur5 receptor activity
ZA201500896B (en) Ethynyl derivatives as modulators of mglur5 receptor activity
IL238381B (en) Transdermal preparations based on propyleneaminoindan
GB201223053D0 (en) Receptor
PL2820010T3 (pl) Pochodne benzofurano-2-sulfonamidu jako modulatory receptora chemokinowego
ZA201403502B (en) Nicotinic receptor non-competitive modulators
GB201213192D0 (en) Support for therapeutic